News - Page 11

Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.

Novartis expect the expansion in North Carolina will add 700 new employees to its ranks. The manufacturing campus will span some 700,000 square feet between new and existing space, Novartis said.

Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for $330 million, the South Korean biosimilar specialist said it will spend another 700 billion won ($478 million) to upgrade

In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its native Empire State. Now,

The company will spend approximately $1.5 billion in capital investments to grow its U.S. plasma-based manufacturing capabilities over the next five years.

South Korea’s Boryung Corporation continues to boost its production footprint by kicking off a project that will double the capacity of its penicillin manufacturing facility in its home country.

Since the start of the month, several drug recalls have entered the FDA’s periphery, affecting products ranging from hospital drugs and potassium deficiency injections to antibiotics and a generic medicine for attention-deficit/hyperactivity

Like with the August cuts, the latest round of layoffs will mostly affect the team based in Harmans, Maryland.

This week on “The Top Line,” we break down what’s known about FDA’s PreCheck, and the parts of the plan that could have the biggest impact on manufacturers.

Cencora plans to spend $1 billion over the next five years to expand its operations in the U.S., including opening a second national distribution center in Ohio.